These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22180287)

  • 1. Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.
    Monk JP; Halabi S; Picus J; Hussain A; Philips G; Kaplan E; Ahles T; Gu L; Vogelzang N; Kelly WK; Small EJ;
    Cancer; 2012 Sep; 118(17):4139-47. PubMed ID: 22180287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
    Leibowitz RL; Tucker SJ
    Oncologist; 2001; 6(2):177-82. PubMed ID: 11306729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy.
    Barqawi AB; Moul JW; Ziada A; Handel L; Crawford ED
    Urology; 2003 Nov; 62(5):872-6. PubMed ID: 14624911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate.
    Brufsky A; Fontaine-Rothe P; Berlane K; Rieker P; Jiroutek M; Kaplan I; Kaufman D; Kantoff P
    Urology; 1997 Jun; 49(6):913-20. PubMed ID: 9187700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group.
    Kirby R; Robertson C; Turkes A; Griffiths K; Denis LJ; Boyle P; Altwein J; Schröder F
    Prostate; 1999 Jul; 40(2):105-14. PubMed ID: 10386471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
    Oh WK; Manola J; Bittmann L; Brufsky A; Kaplan ID; Smith MR; Kaufman DS; Kantoff PW
    Urology; 2003 Jul; 62(1):99-104. PubMed ID: 12837431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
    Bañez LL; Blake GW; McLeod DG; Crawford ED; Moul JW
    BJU Int; 2009 Aug; 104(3):310-4. PubMed ID: 19239458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined finasteride and flutamide therapy in men with advanced prostate cancer.
    Ornstein DK; Rao GS; Johnson B; Charlton ET; Andriole GL
    Urology; 1996 Dec; 48(6):901-5. PubMed ID: 8973674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy.
    Corn BW; Valicenti RK; Mulholland SG; Hyslop T; Gomella L
    Urology; 1998 May; 51(5):782-7. PubMed ID: 9610592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit study.
    Walczak JR; Carducci MA;
    Urology; 2003 Dec; 62 Suppl 1():141-6. PubMed ID: 14747052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate.
    Tay MH; Kaufman DS; Regan MM; Leibowitz SB; George DJ; Febbo PG; Manola J; Smith MR; Kaplan ID; Kantoff PW; Oh WK
    Ann Oncol; 2004 Jun; 15(6):974-8. PubMed ID: 15151957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?
    Labrie F; Candas B; Gomez JL; Cusan L
    Urology; 2002 Jul; 60(1):115-9. PubMed ID: 12100935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
    McKay RR; Gray KP; Hayes JH; Bubley GJ; Rosenberg JE; Hussain A; Kantoff PW; Taplin ME
    Cancer; 2015 Aug; 121(15):2603-11. PubMed ID: 25903013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed.
    Ornstein DK; Smith DS; Andriole GL
    Urology; 1998 Dec; 52(6):1094-7. PubMed ID: 9836561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.
    Kobayashi M; Nukui A; Suzuki K; Kurokawa S; Morita T
    Int J Clin Oncol; 2011 Dec; 16(6):630-6. PubMed ID: 21512893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma.
    Fleshner NE; Fair WR
    Br J Urol; 1996 Dec; 78(6):907-10. PubMed ID: 9014718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer.
    Small EJ; Srinivas S
    Cancer; 1995 Oct; 76(8):1428-34. PubMed ID: 8620419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.